Clinician’s Brief podcast revisits OA pain management beyond NSAIDs

VERSION 2 — FULL ANALYSIS

Clinician’s Brief has released a sponsored podcast, Osteoarthritis Pain: Beyond NSAIDs with Dr. Robin Downing, that brings a familiar clinical issue back into focus: how practices should manage chronic OA pain when treatment options are expanding, but case complexity hasn’t gotten any simpler. In the episode, host Beth Molleson, DVM, speaks with Downing about implementing more complete pain-control strategies and helping pet parents recognize pain earlier and more accurately. The sponsor is PRN Pharmacal. (cliniciansbrief.com)

That framing fits where the profession has been heading for several years. The 2022 AAHA Pain Management Guidelines describe pain management as a continuum of assessment, treatment, reassessment, and plan revision, and they explicitly favor proactive, preemptive, multimodal care over a reactive approach. For chronic OA pain, the guidelines also emphasize that pet parent input is essential, and they point clinicians toward structured tools such as owner questionnaires and clinical metrology instruments to make assessment more reproducible. (aaha.org)

Downing is a notable voice in that conversation. AAHA recently highlighted her as hospital director of The Downing Center for Animal Pain Management and summarized her view that patients need “truly multimodal” pain plans that include physical medicine modalities alongside pharmaceutical and nutraceutical support. That perspective is consistent with the Clinician’s Brief episode description, which says the discussion centers on complete and effective pain-control strategies, not just drug selection. It also matches the broader editorial direction of Clinician’s Brief’s recent mobility coverage: in a separate sponsored podcast on mobility and joint health, sports medicine and rehabilitation specialist Matt Brunke, DVM, DACVSMR, emphasized management strategies beyond medications and supplements and called attention to the everyday functional impact of mobility loss in both dogs and cats. (aaha.org)

That added context matters because OA and mobility decline are not just canine issues, and they are not only pharmacology problems. In the Brunke discussion, cats were singled out as easy to overlook despite substantial need: he noted that many indoor cats are obese, less active, living longer, and developing primary osteoarthritis that can quietly erode function and quality of life. That complements the Downing podcast’s focus on better pain recognition by underscoring a practical point for general practice teams: some patients with chronic joint pain are missed not because therapies are unavailable, but because the mobility problem is normalized, underreported, or harder for owners to recognize early.

The timing also matters because OA pain management is evolving quickly. Anti-nerve growth factor monoclonal antibodies have added a new option to the treatment landscape: FDA approved Librela for control of pain associated with osteoarthritis in dogs in May 2023, and more recent published data have compared bedinvetmab with meloxicam, reporting equivalent pain relief in a randomized clinical trial. At the same time, safety scrutiny has intensified, with a separate 2025 Frontiers paper arguing that musculoskeletal adverse events linked to bedinvetmab warrant closer attention. Taken together, that leaves clinicians navigating a more crowded and more closely watched therapeutic field than they were even a few years ago. (fda.gov)

Industry and expert messaging has increasingly converged around one point: OA pain rarely has a one-size-fits-all answer. The AAHA guidelines rank NSAIDs and anti-NGF monoclonal antibodies among key therapies for chronic OA pain, but they also pair those with supportive care, omega-3s, environmental modification, activity support, weight optimization, and, when indicated, rehabilitation and surgery. In other words, the current standard conversation is less about choosing a single winner and more about building a layered plan that fits the patient, the household, and the burden of care for the pet parent. Brunke’s mobility-focused comments reinforce that same model from a function-first angle: keeping pets active after injury, through arthritis, or during surgical recovery often depends on practical day-to-day support, not just adding another product. (aaha.org)

Why it matters: For general practitioners, the practical takeaway is that OA management is becoming more systematized and more communication-heavy. Clinics are being asked to identify chronic pain earlier, document it more consistently, explain tradeoffs more clearly, and revisit plans more often. A podcast like this may be sponsored, but the underlying issue is real: many OA patients still need better recognition of pain, better follow-up, and better integration of rehab, weight management, home modification, and medication strategy. That is true for dogs, but also for cats whose obesity, inactivity, and age-related joint disease may present as subtle mobility or behavior changes rather than obvious lameness. It’s especially important as pet parents arrive with growing awareness of options, including biologics and supplements, but often uneven understanding of evidence and risk. (cliniciansbrief.com)

What to watch: The next phase of this story is likely to center on how practices operationalize multimodal OA care amid changing evidence, including further head-to-head efficacy data, post-market safety monitoring for newer agents, and continued pressure to show pet parents measurable quality-of-life gains over time. Expect that conversation to keep expanding beyond analgesic choice alone and toward mobility-centered care plans that combine drugs, rehabilitation, weight control, environmental support, and better recognition of chronic pain in both dogs and cats. (frontiersin.org)